Does Rallies show 13F holders for ALT?

Yes. Rallies tracks hedge fund and 13F ownership data for ALT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALT. It does not provide personalized investment advice.

ALT (Altimmune, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Altimmune, Inc. Common Stock (ALT) is a publicly traded Healthcare sector company. As of May 21, 2026, ALT trades at $2.81 with a market cap of $544.53M and a P/E ratio of -2.79. ALT moved +3.28% today. Year to date, ALT is -31.05%; over the trailing twelve months it is -51.79%. Its 52-week range spans $2.56 to $11.16. Analyst consensus is buy with an average price target of $14.30. Rallies surfaces ALT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALT stock?

Hedge funds tracked by Rallies that own ALT include Sculptor Capital, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Altimmune, Inc. Common Stock.

ALT Key Metrics

Key financial metrics for ALT
Metric	Value
Price	$2.81
Market Cap	$544.53M
P/E Ratio	-2.79
EPS	$-1.00
Dividend Yield	0.00%
52-Week High	$11.16
52-Week Low	$2.56
Volume	9.18K
Avg Volume	0
Revenue (TTM)	$41.00K
Net Income	$-88.09M
Gross Margin	0.00%

Top Hedge Funds Holding ALT

Sculptor Capital holds 276.70K shares of ALT, changed +0.00% as of Dec 31, 2025.
Mangrove Partners holds 239.28K shares of ALT, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 27.60K shares of ALT, changed +0.00% as of Mar 31, 2026.

Latest ALT News

Altimmune Q1 Call Reveals $150M Cash Cushion and Pipeline Advancements — May 14, 2026
Altimmune Q1 net loss narrows to $0.18 per share, stock jumps 7.5% — May 13, 2026
Altimmune Bolsters Cash to $535M, Eyed Phase 3 MASH Trial Launch in H2 2026 — May 13, 2026
Altimmune CEO Acquires 20,000 Shares Before Phase 3 Pemvidutide Trial — Mar 9, 2026
Altimmune’s Pemvidutide Wins FDA Breakthrough, Secures $340M Runway — Mar 6, 2026

Recent ALT Insider Trades

GILL JOHN bought 9.20K (~$31.35K) on Apr 6, 2026.
WEAVER GREGORY L bought 10.00K (~$31.50K) on Apr 1, 2026.
Durso Jerome Benedict bought 15.00K (~$47.10K) on Apr 1, 2026.

ALT Analyst Consensus

7 analysts cover ALT: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.30.

Common questions about ALT

Who owns ALT stock?: Hedge funds tracked by Rallies that own ALT include Sculptor Capital, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Altimmune, Inc. Common Stock.
Does Rallies show 13F holders for ALT?: Yes. Rallies tracks hedge fund and 13F ownership data for ALT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALT. It does not provide personalized investment advice.